• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Methylcobalamin

Methylcobalamin

Background

Methylcobalamin is the biologically active form of vitamin B12 and is used in Japan
to treat peripheral neuropathy and megaloblastic anaemia. Methylcobalamin has
the ability to decrease levels of homocysteine, a molecule that can contribute to
neuronal degeneration which led to it being considered as a potential candidate for
ALS treatment.

Based on some small early-stage human studies, a Japanese pharmaceutical
company, Eisai, supported a Phase II/III clinical trial.

This trial was run between 2007 and 2014 in 51 sites in Japan with 360 participants.
The treatment regime was quite long (3.5 years)
(https://clinicaltrials.gov/ct2/show/NCT00444613), with participants receiving
placebo, or 25 or 50mg methylcobalamin twice a week via intramuscular injections.
Results from this initial trial showed that receiving methylcobalamin did not lead to
any significant differences either in survival rates or ALS functional scores, when
compared with placebo.

However, subsequent analysis of the data showed that methylcobalamin seemed to
have an effect in a sub-group of participants who received treatment earlier in their
disease journey (a year or less after symptom onset). These participants showed a
statistically significant decrease in the rate of disease progression (i.e., a decrease in
the rate of decline of the ALSFRS-R score), and also survived longer or took longer to
require ventilation support compared with the placebo group. The outcome of the
trial was published in January 2019 (“Ultra-high-dose methylcobalamin in
amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study”
https://jnnp.bmj.com/content/90/4/451).

However, this data was not considered sufficient for approval as an ALS/MND
treatment by the Japanese authorities because it was done after the initial study
results were obtained (post-hoc analysis) and such observations can be misleading.
In an attempt to validate the post-hoc findings, a new Phase 3 trial, JETALS
(https://clinicaltrials.gov/ct2/show/NCT03548311), was undertaken in 2017, which
focused on participants who seemed to respond well to the treatment from the first
trial i.e. those whose symptoms had begun within one year of enrollment and who
progressed at a moderate rate (defined as a 1–2 point decrease in their ALSFRS-R
scores over the three months preceding the trial).

Trial Design and Results

Participants received twice-weekly injections of either 50 mg of methylcobalamin or
a placebo for 16 weeks. An open-label extension was then made available to all trial
participants in which they will receive the therapy until March 2024.

The initial 16-week trial met its primary outcome, with methylcobalamin-treated
participants showing a 43% slower disease progression as measured by their ALSFRSR scores than those given a placebo (2.66 vs. 4.63 points over 16-weeks). Participants
receiving Riluzole as well as methylcobalamin showed similar results. There was no
difference in side effects of the drug between placebo or methylcobalamin-treated
participants. Although there were statistically significant reductions in ALSFRS-R,
other measures such as muscle strength, forced vital capacity and the ALSAQ-40 total
score, were not changed.

The results from this trial were published in May 2022 – “Efficacy and Safety of
Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis A
Randomized Clinical Trial” https://jamanetwork.com/journals/jamaneurology/articleabstract/2792228

There are several things to take into account for this study. As the drug was only
tested on participants early in the disease process, it is not clear if the treatment
would be appropriate for participants with more advanced disease. Methylcobalamin
treatment results in a marked change in urine colour which could mean that
participants may have known whether they were receiving placebo or
methylcobalamin and that could influence results (including a potential “nocebo”
effect). The fact that the placebo group appeared to worsen their rate of disease
progression once the trial commenced perhaps supports these concerns of a
potential unblinding effect. The open label extension data may well help to offset any
possible confounding effects. It should be considered that the 16-week trial duration
is shorter than most other trials which usually have a minimum 24-week duration.
Data from the open-label extension will be informative for the longer-term benefits
of this drug.

Summary

The SAC believes that the initial trial and follow-up stage 3 trial have demonstrated
promising results in a subset of early stage participants. The company have stated
they will file for approval from the Japanese authorities in 2023. Due to the short trial
duration and potential confounding effects (hastened placebo decline, possible
unblinding), it is difficult at this time to know the true efficacy, if any, of ultra highdose methylcobalamin in ALS/MND and any consideration of use should be at a
clinician’s discretion. The SAC suggests that data from the open label extension be
incorporated into analysis to better assess the efficacy of this treatment.

Updated March 2023

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • ILB – Tikomed
  • Kadimastem – AstroRx
  • Methylcobalamin
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Neuronata-R/Lenzumestrocel
  • NeuroSense – PrimeC
  • Neuvivo – NP001
  • T Regulatory Cell Therapies
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials

  • Chih Ching Darren Wong, MND Malaysia

    Chih Ching Darren Wong, MND Malaysia

  • Liz Ogg, Diagnosed 2013 , MND Scotland, UK

    Liz Ogg, Diagnosed 2013 , MND Scotland, UK

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • Ali Var, Turkey

    Ali Var, Turkey

  • Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

    Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Fabio Correia

    Fabio Correia

  • Chris McCauley, Diagnosed 2015 , ALS Canada

    Chris McCauley, Diagnosed 2015 , ALS Canada

  • Angie Bordaen, Diagnosed 2014,  ALS Liga België, Belgium

    Angie Bordaen, Diagnosed 2014, ALS Liga België, Belgium

  • Carlos Alberto Báez Murillo, ACELA, Colombia

    Carlos Alberto Báez Murillo, ACELA, Colombia

  • Glen Elison,  ALS Hope Foundation,  Diagnosed 2019,  USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Andrea Zicchieri, Associazione conSLAncio Onlus, Italy

    Andrea Zicchieri, Associazione conSLAncio Onlus, Italy
    AndreaZicchieri_conSLAncioItaly

  • Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

    Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Cath Muir

    Cath Muir
    Cath

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Ian Gale, MND Australia

    Ian Gale, MND Australia

  • Willi Klein

    Willi Klein

  • Margreth Burger-Saile, Diagnosed 2011,  ALS Schweiz,  Switzerland

    Margreth Burger-Saile, Diagnosed 2011, ALS Schweiz, Switzerland

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

    Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

  • 727747090571358167

    727747090571358167

  • Joy Blakeley, Diagnosed 2017 , MND Australia

    Joy Blakeley, Diagnosed 2017 , MND Australia

  • Steven Spencer, Diagnosed 2014 , MND New Zealand

    Steven Spencer, Diagnosed 2014 , MND New Zealand

  • 393647_2252248542053_984912751_n

    393647_2252248542053_984912751_n

  • Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

    Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

  • Sam Hayden-Harler, Motor Neurone Disease (MND) Association, UK

    Sam Hayden-Harler, Motor Neurone Disease (MND) Association, UK

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Kirsten Harley,  Diagnosed 2013,  Australia

    Kirsten Harley, Diagnosed 2013, Australia

  • Richard Clark, MND New Zealand,  Diagnosed 2011

    Richard Clark, MND New Zealand, Diagnosed 2011

  • Steve Gallagher, ALS Society of Canada

    Steve Gallagher, ALS Society of Canada
    Picture1

  • Mauril Bélanger, Diagnosed 2015 , ALS Canada

    Mauril Bélanger, Diagnosed 2015 , ALS Canada

  • Ailsa Malcolm-Hutton, Diagnosed 2013,  MND Association of England, Wales and N Ireland

    Ailsa Malcolm-Hutton, Diagnosed 2013, MND Association of England, Wales and N Ireland

  • Peng Yi-Wen

    Peng Yi-Wen

  • Ali Var, Turkey

    Ali Var, Turkey

  • Feng Gin Sun, Diagnosed 2014 , Shaanxi ALS Association, China

    Feng Gin Sun, Diagnosed 2014 , Shaanxi ALS Association, China

  • Irene McCaughey, Diagnosed 2011,  MND Australia

    Irene McCaughey, Diagnosed 2011, MND Australia

  • Mark Miller

    Mark Miller

  • H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

    H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Armando González Gómez, ACELA, Colombia

    Armando González Gómez, ACELA, Colombia

  • Mary Thomas, Diagnosed 2013 , MND Australia

    Mary Thomas, Diagnosed 2013 , MND Australia

  • Maria Santos Garcia Tellez, Diagnosed 2017 , FYADENMAC, Mexico

    Maria Santos Garcia Tellez, Diagnosed 2017 , FYADENMAC, Mexico

  • Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

    Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

  • Dr Shelly Hoover

    Dr Shelly Hoover

  • Claudia Cominetti, Associazione conSLAncio Onlus,  Italy

    Claudia Cominetti, Associazione conSLAncio Onlus, Italy

  • Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

    Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

  • Tammy Moore and Eddy Lefrancois

    Tammy Moore and Eddy Lefrancois

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login